← All examples Complex stack · CVR optionality

LUMRYZ (sodium oxybate ER)

Once-nightly narcolepsy · originated by Avadel · Acquired by Alkermes February 2026 (~$2.1B + CVR)

Layer 01 · Status

Clinical

Approved narcolepsy product with a contingent second-indication kicker that could double the rate.

FDA approved 2023 2024 sales $169M 2025 guidance $265–275M IH Phase 3 ongoing Patents to ~2036
0 $750M 2023 2024 2025E 2026E 2028E Peak
Net sales — narcolepsy only, $M
Narcolepsy launch curve. The contingent IH approval would add a second curve roughly proportional to indication share.

Layer 02 · Who pays?

Royalty stack

Tiered, indication-contingent rates plus a contingent value right tied to a Phase 3 readout. Standard databases miss most of this.

Narcolepsy royalty

3.85%

Reducible to 3.75% on net sales through Feb 2036. Jazz pays Avadel/Alkermes on net narcolepsy sales.

Future-indication royalty

10%

Reducible to 9.5%. On any approved indications including idiopathic hypersomnia (IH) from no earlier than March 2028.

The 10% IH-contingent rate is the interesting structural feature. A standard royalty database flags this asset as "3.85% narcolepsy royalty" and stops. The 10% kicker plus the IH probability is what determines whether the royalty is worth acquiring.

3.85%
+6.15%
0% 12%

Base rate (navy) is contractual. The IH kicker (gold) crystallises only on indication-specific approval from March 2028.

Layer 03 · Fair rate?

Rate comparables

Sleep / CNS comps, plus indication-contingent step-up structures.

The 3.85% base rate sits below the median CNS approved-asset comp (4.8%) but the contingent 10% IH kicker, if it triggers, places the blended rate well above median. The structure matches what we see in roughly 12% of the indication-contingent deals in our corpus, almost all of them post-2020.

Layer 04 · Triggers

Milestones & events

What CFC saw before the market — recent inputs that move the deal.

  • Oct 2025 $90M Jazz to Avadel settlement closes outstanding patent litigation
  • Feb 2026 Alkermes acquires Avadel at $18.50/share + $1.50 CVR contingent on IH approval by end-2028, total ~$2.1B
  • Jul 2025 Takeda oveporexton (TAK-861) Phase 3 hits in narcolepsy; H2 2026 launch expected. CFC competitive rating upgraded Watch → High.

Layer 05 · Threats

Competitors

Why the IH probability and the oveporexton timing both matter for the same royalty.

Takeda oveporexton (TAK-861) Generic sodium oxybate (Hikma) Xywav (Jazz)

Oveporexton is the structural threat to the narcolepsy base. If it launches H2 2026 and captures 25% of new patient starts within two years, our model knocks ~30% off LUMRYZ peak narcolepsy royalty. That makes the IH kicker proportionally more valuable, not less, to anyone underwriting today.

Layer 06 · Value

What CFC saw before the market

Three calibration anchors the engine produced for this stack ahead of the Alkermes transaction.

Anchor 1 · Litigation

Settlement risk priced

Jazz–Avadel litigation overhang resolved at $90M in October 2025. Without that overhang, an acquirer underwrites a narrower band of legal risk and can pay materially more.

Anchor 2 · Optionality

IH kicker dominates

At a market-implied ~40% IH approval probability by end-2028, the 10% kicker contributes a meaningful slice of fair value. Below 25% and the royalty trades like a narcolepsy-only asset.

Anchor 3 · Competition

Oveporexton-resistant

The IH indication is structurally less exposed to oveporexton's narcolepsy-first launch path, which makes the IH kicker partially uncorrelated with the base-rate erosion risk.

Complex royalty stacks are not the exception. They are most of the market.

The single line "3.85% narcolepsy royalty" describes the asset only at first glance. The full picture, including indication-contingent tiers, litigation history, and competitive substitution, is what determines whether the position is worth acquiring at any given price.